Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Anti-von Willebrand Factor Nanobody, Caplacizumab1件: Caplacizumab (caplacizumab-yhdp)1件: Caplacizumab (Caplacizumab, Caplacizumab-yhdp) 💬 1件: VWF 💬 9件: Complement and coagulation cascades, Coronavirus disease, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Integrin signaling, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬
2Anti-von Willebrand Factor Nanobody, INN = Caplacizumab1件: Caplacizumab (caplacizumab-yhdp)1件: Caplacizumab (Caplacizumab, Caplacizumab-yhdp) 💬 1件: VWF 💬 9件: Complement and coagulation cascades, Coronavirus disease, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Integrin signaling, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬
3Cablivi®Product Name: Cablivi®Product Code: ALX0081Pharmaceutical Form: Powder and solvent for solution for injectionINN or Proposed INN: CaplacizumabCAS Number: 915810-67-2Current Sponsor code: ALX0081Other descriptive name: Nanobody directed towards the human A1 domain of von Willebrand factorConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 12.5-Trade Name: Cablivi®Product Name: Cablivi®Product Code: ALX0081Pharmaceutical Form: Powder and solvent for solution for injectionINN or Proposed INN: CaplacizumabCAS Number: 915810-67-2Current Sponsor code: ALX0081Other descriptive name: Nanobody directed towards the human A1 domain of von Willebrand factorConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 12.5-----1件: 64 💬
4Caplacizumab1件: Caplacizumab (caplacizumab-yhdp)1件: Caplacizumab (Caplacizumab, Caplacizumab-yhdp) 💬 1件: VWF 💬 9件: Complement and coagulation cascades, Coronavirus disease, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Integrin signaling, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬2件: 63, 64 💬
5Caplacizumab (ALX-0081)1件: Caplacizumab (caplacizumab-yhdp)1件: Caplacizumab (Caplacizumab, Caplacizumab-yhdp) 💬 1件: VWF 💬 9件: Complement and coagulation cascades, Coronavirus disease, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Integrin signaling, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬
6Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081)1件: Caplacizumab (caplacizumab-yhdp)1件: Caplacizumab (Caplacizumab, Caplacizumab-yhdp) 💬 1件: VWF 💬 9件: Complement and coagulation cascades, Coronavirus disease, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Integrin signaling, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬
7Caplacizumab (an anti-von Willebrand Factor Nanobody)1件: Caplacizumab (caplacizumab-yhdp)1件: Caplacizumab (Caplacizumab, Caplacizumab-yhdp) 💬 1件: VWF 💬 9件: Complement and coagulation cascades, Coronavirus disease, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Integrin signaling, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬